Akt1, 2, and 3 are serine/threonine protein kinases in the phosphatidylinositol 3 (PI3)-kinase signalling pathway that play a critical role in the regulation of cell proliferation and survival.1,2 Following recruitment of Akt to the plasma membrane, phosphorylation at threonine 308 and serine 473 (Akt1 numbering) by phosphoinositide-dependent kinases (PDK) 1 and 2 results in full activation of the enzyme. CAY10567 is an Akt1 translocation inhibitor. At a concentration of 12.5 µM, it prevents the translocation of Akt1 by apparently compromising the function of the PH domain. A structurally similar compound inhibits kinase activity in vitro with an EC50 value of 12 µM by binding to the kinase domain.3 CAY10567 also inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) with an IC50 value of 79 µM. 4
1
Vivanco, I., and Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer2489-501(2002).
2
Hennessy, B.T., Smith, D.L., Ram, P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov4988-1004(2005).
3
Lundholt, B.K., Linde, V., Loechel, F., et al. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN cell 3000 analyzer. J Biomol Screen10(1)20-29(2005).
4
Rong, F., Chow, S., Yan, S., et al. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett171663-1666(2007).
Synonyms
BML-257
Formal Name
2,3-diphenyl-6-quinoxalinecarboxylic acid
CAS Number
32387-96-5
Molecular Formula
C21H14N2O2
Formula Weight
326.4
Formulation
A crystalline solid
Purity
>98%
λmax
249, 351 nm
Stability
2 years
Storage
-20°C
Shipping
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
OC(=O)c1ccc2nc(c3ccccc3)c(nc2c1)c1ccccc1
Background Reading
Vivanco, I., and Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer2489-501(2002).
Hennessy, B.T., Smith, D.L., Ram, P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov4988-1004(2005).
Rong, F., Chow, S., Yan, S., et al. Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett171663-1666(2007).
Lundholt, B.K., Linde, V., Loechel, F., et al. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN cell 3000 analyzer. J Biomol Screen10(1)20-29(2005).